Pelthos Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $71.71M
- P/E (TTM)
- –
- Dividend yield
- –
About Pelthos Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Pelthos Therapeutics Inc. is a biopharmaceutical company that commercializes treatments for dermatological conditions and pain management. The company maintains a portfolio of three therapies approved by the FDA: ZELSUVMI, a topical gel for molluscum contagiosum; XEPI, an antimicrobial cream for impetigo; and XEGLYZE, a pediculicide for head lice. In addition, the firm develops clinical-stage, non-opioid pain candidates targeting sodium channels. Its customer base includes adult and pediatric patients with skin conditions, as well as prescribing healthcare professionals such as pediatricians and dermatologists. The company distributes its commercial therapies through retail chains, mail-order services, and digital pharmacies.
The company conducts its primary operations from a leased 19,265-square-foot facility in Durham, North Carolina, which houses administrative offices, research laboratories, warehouses, and manufacturing space for active pharmaceutical ingredients. Pelthos holds worldwide rights to its head lice therapy, global rights excluding Japan for its molluscum contagiosum treatment, and rights within the United States for its impetigo treatment.
Summary of the business section of Pelthos Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Pelthos Therapeutics Inc.
- Founded
- 2021
- Headquarters
- Durham, NC
- Address
- 4020 Stirrup Creek Drive, Suite 110 27703
- Phone
- (919) 908-2422
- Employees
- 92, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Hartford, Connecticut
Stock & identifiers
- Ticker
- PTHS
- Exchange
- NYSE
- IPO date
- Feb 20, 2024
- Shares outstanding
- 4M, Aug 10, 2026
- Public float
- $6.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jul 2, 2025; 1-for-10 reverse, Jul 1, 2025
- SEC CIK
- 1919246
- CUSIP
- 171126204
- ISIN
- US1711262048
- EIN
- 86-3335449
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Scott M. Plesha | CEO and President, Director | 83,678 |
| Knuettel Francis II | CFO, Treas & Secty | 40,841 |
| John M. Gay | Chief Financial Officer | 30,518 |
| Sai Rangarao | Chief Commercial Officer | 30,518 |
| Matthew Pauls | Director | 14,458 |
| Ezra M. Friedberg | Director | 203,114 |
| Peter Greenleaf | Director | 23,884 |
| Todd C. Davis | Director | 1,575,331 |
| Richard Malamut | Director | 28,462 |
| Richard B. Baxter | Director | 19,108 |
| Andrew J. Einhorn | Director | 12,000 |
| Pharmaceuticals Inc Ligand | Director | 1,500,000 |
| Chia-Lin Simmons | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, the Company had a total of 92 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 21, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Sep 16, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jul 2, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| May 27, 2025 | Name change | Name changed from Channel Therapeutics Corp to Pelthos Therapeutics Inc. |
| Apr 17, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 15, 2024 | Name change | Name changed from Chromocell Therapeutics Corp to Channel Therapeutics Corp |
| Apr 1, 2024 | Late filing | Notification of late filing |
| Feb 20, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 15, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |